Gum Tech sales & earnings
This article was originally published in The Tan Sheet
Executive Summary
"Growing consumer acceptance of the Zicam brand" spurred sales 17.9% to $5.5 mil. in fourth quarter, up 48.6% to $16.1 mil. for the year, Phoenix-based firm reports Feb. 28. Net loss for FY '01 improved 22.2% to $4.8 mil. Gum Tech's plans for 2002 include corporate name change, continued aggressive advertising, expanded R&D, application for CHPA membership and strengthening of senior management, firm says...You may also be interested in...
Prenatal Vitamin D Benefit In Preventing Childhood Asthma Fades By Age 6
University of Rochester researchers say a benefit of daily prenatal vitamin D in preventing asthma in children up to 3 found in their 2016 study doesn't extend until age 6. They encourage more research, including analyzing whether supplementation should continue in young children.
UK Reveals Plans For ‘Dynamic’ Post-Brexit Regulatory System
At the end of the Brexit transition period, the UK will be charting its own course through the often choppy seas of medicines regulation. While it plans to retain the existing EU rules that have been transposed into domestic legislation, it also wants the freedom to tailor its regulations in areas like clinical trials, advanced therapies and product labeling.
Win For Axonics As England’s NICE Says Rechargeable Neuromodulation Is Cost-Effective
Health technology assessment body NICE is consulting on draft guidance that recommends Axonics' device for overactive bladder.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: